keyword
MENU ▼
Read by QxMD icon Read
search

Telbivudine

keyword
https://www.readbyqxmd.com/read/28522916/early-hepatitis-b-viral-dna-clearance-predicts-treatment-response-at-week-96
#1
Xiao-Yu Fu, De-Ming Tan, Cui-Mei Liu, Bin Gu, Li-Hua Hu, Zhong-Tian Peng, Bin Chen, Yuan-Lin Xie, Huan-Yu Gong, Xiao-Xuan Hu, Lian-Hui Yao, Xiao-Ping Xu, Zheng-Yuan Fu, Lang-Qiu He, Si-Hai Li, Yun-Zhu Long, De-Hui Li, Ji-Long Gu, Shi-Fang Peng
AIM: To investigate whether hepatitis viral DNA load at 24 wk of treatment predicts response at 96 wk in patients with chronic hepatitis B. METHODS: A total of 172 hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients who received initial treatment at 16 tertiary hospitals in Hunan Province, China were enrolled in this study. All patients received conventional doses of lamivudine and adefovir dipivoxil, telbivudine, entecavir dispersible tablets, or entecavir tablets for 96 wk...
April 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28478758/-rhabdomyolysis-associated-with-telbivudin-therapy-report-of-a-case
#2
Almudena Mancebo González, María José Peñalver Jara, Laura Menéndez Naranjo, Ana Patricia Navarro Egea
No abstract text is available yet for this article.
May 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28445403/detection-of-hepatitis-b-virus-m204i-mutation-by-quantum-dot-labeled-dna-probe
#3
Cheng Zhang, Yiping Chen, Xinmiao Liang, Guanhua Zhang, Hong Ma, Leng Nie, Yu Wang
Quantum dots (QDs) are semiconductor nanoparticles with a diameter of less than 10 nm, which have been widely used as fluorescent probes in biochemical analysis and vivo imaging because of their excellent optical properties. Sensitive and convenient detection of hepatitis B virus (HBV) gene mutations is important in clinical diagnosis. Therefore, we developed a sensitive, low-cost and convenient QDs-mediated fluorescent method for the detection of HBV gene mutations in real serum samples from chronic hepatitis B (CHB) patients who had received lamivudine or telbivudine antiviral therapy...
April 26, 2017: Sensors
https://www.readbyqxmd.com/read/28434087/hepatitis-b-during-pregnancy-in-endemic-areas-screening-treatment-and-prevention-of-mother-to-child-transmission
#4
REVIEW
Naichaya Chamroonkul, Teerha Piratvisuth
The proper management of pregnant women infected with hepatitis B virus (HBV) is necessary to prevent maternal and fetal morbidity and mortality and to protect the baby from HBV infection. In the majority of cases, vertical transmission can be prevented with a universal screening program, HBV vaccine immunoprophylaxis, and administration of hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load (>200,000 or >1,000,000 IU/ml, depending on the guideline), the chance of immunoprophylaxis failure remains high...
June 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28422442/effect-of-hepatitis-b-virus-subgenotype-on-antiviral-response-in-nucleoside-treated-hepatitis-b-e-antigen-positive-patients
#5
Sheng Shen, Xieer Liang, Kamal Hamed, Yasuhito Tanaka, Katsumi Omagari, Rong Fan, Qing Xie, Deming Tan, Bin Zhou, Ji-Dong Jia, Jinlin Hou, Jian Sun
BACKGROUND: Previous studies have reported that hepatitis B virus (HBV) genotype is not a predictor of treatment response with nucleos(t)ide analogue (NUC) therapy. However, the impact of subgenotype on treatment response is unknown. AIM: To identify the effect of HBV subgenotype on treatment response. METHODS: In this retrospective study, the derivation dataset comprised patients from the EFFORT study (NCT00962533) telbivudine monotherapy group; patients infected with genotypes B or C from the GLOBE (NCT00057265) and 015 (NCT00131742) studies formed the validation dataset...
April 19, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28407735/telbivudine-treatment-started-in-early-and-middle-pregnancy-completely-blocks-hbv-vertical-transmission
#6
Weihui Sun, Shangfei Zhao, Lei Ma, Anhua Hao, Bo Zhao, Lin Zhou, Fengzhu Li, Mingquan Song
BACKGROUND: To evaluate the efficacy and safety of treating HBV-positive mothers with telbivudine in early and middle pregnancy to prevent mother-to-infant HBV transmission. METHODS: The subject population comprised pregnant women with chronic hepatitis B (CHB; n = 188) from January 2013 to June 2015, with HBV DNA ≥1.0 × 10(7)copies/mL and increased alanine aminotransferase levels. Groups A (n = 62) and B (n = 61) were treated with telbivudine starting at 12 weeks or 20-28 weeks after gestation, respectively...
April 13, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28386259/elevated-expression-of-chemokine-cxcl13-in-chronic-hepatitis-b-patients-links-to-immune-control-during-antiviral-therapy
#7
Chao Liu, Xuan Huang, Melanie Werner, Ruth Broering, Jun Ge, Yongyin Li, Baolin Liao, Jian Sun, Jie Peng, Mengji Lu, Jinlin Hou, Xiaoyong Zhang
C-X-C-chemokine ligand 13 (CXCL13), the ligand for C-X-C chemokine receptor type 5 (CXCR5), is a major regulator of B-cell trafficking and plays an integral role in age-dependent clearance of hepatitis B virus (HBV) in the mouse model. However, the expression and function of CXCL13 in patients with chronic hepatitis B (CHB) remain unknown. By use of liver cell subpopulations isolated from CHB patients, we found that CXCL13 mRNA was abundantly expressed in Kupffer cells (KCs), but not in primary hepatocytes, liver sinusoidal endothelial cells, and hepatic stellate cells...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28373116/telbivudine-attenuates-gentamicin-induced-kidney-injury-in-rats
#8
Cigdem Kader, Mustafa Sunbul, Yavuz Kursad Das, Murat Yarim, Abdulkerim Bedir, Efe Karaca, Mehmet Celikbilek, Resat Ozaras
Nephrotoxicity has been associated with nucleos(t)ide analogues other than telbivudine (LdT). This study investigated the potential effects of LdT and lamivudine (LAM) on renal function in an experimental rat model of gentamicin-induced acute nephrotoxicity. A total of 28 healthy Wistar albino rats were randomly divided into four experimental groups: negative control; positive control (PC); LdT; and LAM. Nephrotoxicity was induced by gentamicin in the LdT, LAM and PC groups. LdT and LAM were administered to two groups for 6 weeks starting on the ninth day...
May 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28351603/predictors-of-hbeag-seroconversion-after-long-term-nucleos-t-ide-analogues-treatment-for-chronic-hepatitis-b-a-multicenter-study-in-real-clinical-setting
#9
Weiyan Yu, Yadong Wang, Chuan Shen, Ru Ji, Li Zhang, Xin Zhao, Miao Su, Ying Zhang, Wenyan He, Jianguo Cao, Yanshuang Hao, Shengpeng Chen, Caiyan Zhao
AIMS: To evaluate the HBeAg seroconversion rate in real clinical setting and explore its predictors in long-term nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B (CHB). METHODS: 251 patients were recruited from January 2001 to September 2009 in four hospitals in Hebei province, China, for this retrospective study. Clinical and laboratory data before and after treatment with lamivudine (LAM, 100mg daily), adefovir (ADV, 10mg daily), telbivudine (LDT, 600mg daily), entecavir (ETV, 0...
March 27, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28345181/hbsag-kinetics-during-treatment-with-nucleos-t-ides-analogues-in-patients-with-hbeag-negative-chronic-hepatitis-b
#10
Athanasia Striki, Spilios Manolakopoulos, Melanie Deutsch, Anastasia Kourikou, George Kontos, Hariklia Kranidioti, Emilia Hadziyannis, George Papatheodoridis
BACKGROUND/AIMS: Serum HBsAg levels might be used as predictor of virological breakthrough or of sustained off-treatment virological response in HBeAg-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. METHODS: We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11, telbivudine: 16) and 86 HBeAg-negative CHB patients under entecavir or tenofovir for a mean of 30 months as the comparison group...
March 26, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28332360/entecavir-to-telbivudine-switch-therapy-in-entecavir-treated-patients-with-undetectable-hepatitis-b-viral-dna
#11
RANDOMIZED CONTROLLED TRIAL
Dong Hyun Kim, Jong Won Choi, Jeong Hun Seo, Yong Suk Cho, Sun Young Won, Byung Kyu Park, Han Ho Jeon, Sang Yun Shin, Chun Kyon Lee
PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase level after the initial 6 months of ETV treatment. MATERIALS AND METHODS: Sixty subjects were randomized to continue with ETV or switch to LdT. Significant difference in baseline characteristics was not found between the two groups. Persistent HBV DNA level of 20-60 IU/mL in three consecutive samples collected three months apart or singly measured HBV DNA level of >60 IU/mL was defined as virological rebound...
May 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28317397/nucleos-t-ide-analogues-for-preventing-hbv-reactivation-in-immunosuppressed-patients-with-hematological-malignancies-a-network-meta-analysis
#12
Min-Yue Zhang, Gui-Qi Zhu, Ji-Na Zheng, Zhang Cheng, Sven Van Poucke, Ke-Qing Shi, Hong-Hui Huang, Fang-Yuan Chen, Ming-Hua Zheng
BACKGROUND: We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis. METHODS: The search identified 28 articles involving 5 different prophylactic regimens covering 1478 participants...
March 29, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28316253/predominance-of-hepatitis-b-virus-genotype-a-among-treated-hiv-infected-patients-experiencing-high-hepatitis-b-virus-drug-resistance-in-nairobi-kenya
#13
Sepha Nyatichi Mabeya, Caroline Ngugi, Raphael Wekesa Lihana, Samoel Ashimosi Khamadi, Anthony Kebira Nyamache
Hepatitis B virus (HBV)-HIV coinfections are becoming common with information on HBV genetic diversity and drug resistance still remaining elusive. To evaluate the HBV genetic diversity and drug resistance-associated mutations among drug-experienced HIV patients, the genetic analysis of the partial HBV-pol-reverse trancriptase gene was successfully sequenced from 13 samples. Analysis of the sequences showed that all (11) the sequences belonged to genotype A. Nucleos(t)ide drug resistance mutations were found in 6 patients...
April 18, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28270871/antiviral-therapy-in-chronic-hepatitis-b-with-mild-acute-exacerbation
#14
Su Lin, Qiaoxia Ye, Mingfang Wang, Yinlian Wu, Zhiyuan Weng, Yueyong Zhu
BACKGROUND: The aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE). METHODS: Treatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (ETV) or telbivudine (LDT)) therapies were retrospectively selected. The HBeAg seroconversion rate, hepatitis B surface antigen (HBsAg) loss rate and the cost-effectiveness of different treatments were compared...
February 2017: Gastroenterology Research
https://www.readbyqxmd.com/read/28261380/adverse-effects-of-oral-antiviral-therapy-in-chronic-hepatitis-b
#15
REVIEW
Bircan Kayaaslan, Rahmet Guner
Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The aim of this article is to review and update the adverse effects of oral NAs. NAs can cause class adverse effects (i.e., myopathy, neuropathy, lactic acidosis) and dissimilar adverse effects. All NAs carry a "Black Box" warning because of the potential risk for mitochondrial dysfunction...
February 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28231660/-effect-of-telbivudine-on-infants-born-to-hbsag-positive-mothers-with-non-hypo-response-to-hepatitis-b-vaccine-during-their-second-and-third-trimesters-of-pregnancy
#16
X X Xu, B Wang, X F Wang, H X Wen, F Zhang, Z Q Yang, H Y Hao, T Wang, X H Shi, Z D Fu, B Wang, S P Wang
Objective: To explore the effect of telbivudine treatment in a prevention program on infants born to HBsAg-positive mothers with non-/hypo-responsiveness to hepatitis B vaccine. Methods: A retrospective cohort study with a total of 321 HBsAg-positive pregnant women and their infants enrolled, was conducted. The mothers were recruited from the Third People' s Hospital of Taiyuan, from July 2011 to January 2013. According to the situation of telbivudine intake in second and third trimesters of pregnancy, the participants were divided into two groups: with telbivudine-treated or as control...
February 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
https://www.readbyqxmd.com/read/28192212/anti-hbv-drugs-suppress-the-growth-of-hbv-related-hepatoma-cells-via-down-regulation-of-hepatitis-b-virus-x-protein
#17
Shuqin Zhang, Shan Gao, Man Zhao, Yunxia Liu, Yanan Bu, Qiulei Jiang, Qiang Zhao, Lihong Ye, Xiaodong Zhang
Chronic infection of hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). Meta-analyses show that adjuvant anti-HBV therapy is effective for HBV-related HCC patients in clinical. However, the significance that anti-HBV drugs depress HCC is poorly understood. Here, we investigated the effects of telbivudine (LdT), entecavir (ETV) and interferon-α2b (IFN-α2b) on HBV-related HCC. Our data showed that the treatment with the drugs significantly suppressed the growth of HBV-expressing hepatoma cells in vitro and in vivo, but failed to work in HBV-free liver cells...
February 9, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28137301/comparison-of-telbivudine-and-entecavir-on-the-change-of-off-treatment-egfr-after-3%C3%A2-years-of-treatment-in-non-cirrhotic-chronic-hepatitis-b-patients
#18
COMPARATIVE STUDY
Yang-Sheng Lin, Shou-Chuan Shih, Horng-Yuan Wang, Ching-Chung Lin, Chen-Wang Chang, Ming-Jen Chen
BACKGROUND: The change of estimated glomerular filtration rate (eGFR) with off-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear. This study is aimed to evaluate the off-treatment eGFR after 3 years of therapy with telbivudine (LdT) or entecavir (ETV) and to assess predictive factors for eGFR improvement. METHODS: From January 2009 to December 2011, we identified NA-naïve patients who were at least 20 years of age diagnosed with compensated CHB...
January 31, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28107377/hbeag-seroconversion-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-long-term-nucleos-t-ide-analog-treatment-a-systematic-review-and-network-meta-analysis
#19
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye
BACKGROUND: HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. METHODS: Network meta-analysis of NA treatment-induced HBeAg seroconversion after 1-2 years of treatment was performed. In addition, NA treatment-induced HBeAg seroconversion after 3-5 years of treatment was systematically evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28103819/telbivudine-versus-entecavir-in-patients-with-undetectable-hepatitis-b-virus-dna-a-randomized-trial
#20
RANDOMIZED CONTROLLED TRIAL
Jihyun An, Young-Suk Lim, Gi-Ae Kim, Seong-Bong Han, Wonhee Jeong, Danbi Lee, Ju Hyun Shim, Han Chu Lee, Yung Sang Lee
BACKGROUND: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain undetectable serum hepatitis B virus (HBV) DNA after initial entecavir treatment. METHODS: In this open-label trial, patients who had serum HBsAg and HBV DNA levels ≥1,000 IU/mL and <60 IU/mL, respectively, following entecavir (0...
January 19, 2017: BMC Gastroenterology
keyword
keyword
2108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"